Pfizer reinforced its leadership in the amyloidosis market by shipping 2.3 million capsules of tafamidis in 2023, sufficient to treat approximately 36,000 patient-years. To address back-orders in Italy and South Korea, the company’s Freiburg manufacturing facility activated a second freeze-drying line in February 2024. This expansion underscores Pfizer’s strategic focus on scaling production of disease-modifying therapies amid rising transthyretin cardiomyopathy diagnoses, which are now captured through routine technetium-pyrophosphate imaging in North America and Japan.

Following a pullback in revenues from its COVID-19 vaccine and antiviral franchise, Pfizer’s dividend yield has risen to around 6.7 percent. Management has reiterated its commitment to sustaining and growing the dividend over time. At recent valuation levels, the forward price-to-earnings ratio stands near 8.7, below the five-year average of 9.7, offering an entry point for investors seeking high income and potential multi-year total returns as new oncology and GLP-1 partnerships begin to ramp.

In a move to reallocate capital toward core growth areas, Pfizer agreed to exit its 11.7 percent stake in ViiV Healthcare for roughly $1.9 billion. This transaction increases Shionogi’s ownership to 21.7 percent and frees up resources for Pfizer to invest further in its late-stage pipeline, including oncology collaborations and next-generation metabolic therapies.